Literature DB >> 25366259

CD95 and CD95L promote and protect cancer stem cells.

Paolo Ceppi1, Abbas Hadji1, Frederick J Kohlhapp1, Abhinandan Pattanayak1, Annika Hau1, Xia Liu2, Huiping Liu2, Andrea E Murmann1, Marcus E Peter1.   

Abstract

CD95 (APO-1/Fas) is a death receptor used by immune cells to kill cancer cells through induction of apoptosis. However, the elimination of CD95 or its ligand, CD95L, from cancer cells results in death induced by CD95R/L elimination (DICE), a type of cell death that resembles a necrotic form of mitotic catastrophe suggesting that CD95 protects cancer cells from cell death. We now report that stimulation of CD95 on cancer cells or reducing miR-200c levels increases the number of cancer stem cells (CSCs), which are more sensitive to induction of DICE than non-CSC, while becoming less sensitive to CD95-mediated apoptosis. In contrast, induction of DICE or overexpression of miR-200c reduces the number of CSCs. We demonstrate that CSCs and non-CSCs have differential sensitivities to CD95-mediated apoptosis and DICE, and that killing of cancer cells can be maximized by concomitant induction of both cell death mechanisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25366259      PMCID: PMC4417339          DOI: 10.1038/ncomms6238

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  49 in total

Review 1.  Fas ligand-induced apoptosis.

Authors:  S Nagata
Journal:  Annu Rev Genet       Date:  1999       Impact factor: 16.830

2.  Fas engagement accelerates liver regeneration after partial hepatectomy.

Authors:  J Desbarats; M K Newell
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity.

Authors:  K Aoki; M Kurooka; J J Chen; J Petryniak; E G Nabel; G J Nabel
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 4.  The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Authors:  Simone Brabletz; Thomas Brabletz
Journal:  EMBO Rep       Date:  2010-08-13       Impact factor: 8.807

Review 5.  Non-apoptotic Fas signaling.

Authors:  Harald Wajant; Klaus Pfizenmaier; Peter Scheurich
Journal:  Cytokine Growth Factor Rev       Date:  2003-02       Impact factor: 7.638

Review 6.  Killing mechanisms of cytotoxic lymphocytes.

Authors:  G Berke
Journal:  Curr Opin Hematol       Date:  1997-01       Impact factor: 3.284

7.  Antitumor effect of locally produced CD95 ligand.

Authors:  K Seino; N Kayagaki; K Okumura; H Yagita
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

8.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

9.  CD95 promotes tumour growth.

Authors:  Lina Chen; Sun-Mi Park; Alexei V Tumanov; Annika Hau; Kenjiro Sawada; Christine Feig; Jerrold R Turner; Yang-Xin Fu; Iris L Romero; Ernst Lengyel; Marcus E Peter
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

10.  Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs.

Authors:  Masakazu Kamata; Min Liang; Shirley Liu; Yoshiko Nagaoka; Irvin S Y Chen
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

View more
  36 in total

1.  Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.

Authors:  Clara H Karches; Mohamed-Reda Benmebarek; Moritz L Schmidbauer; Mathias Kurzay; Richard Klaus; Martina Geiger; Felicitas Rataj; Bruno L Cadilha; Stefanie Lesch; Constanze Heise; Ramona Murr; Johannes Vom Berg; Martin Jastroch; Daniel Lamp; Jian Ding; Peter Duewell; Gerhard Niederfellner; Claudio Sustmann; Stefan Endres; Christian Klein; Sebastian Kobold
Journal:  Clin Cancer Res       Date:  2019-07-08       Impact factor: 12.531

2.  CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Authors:  Abdul S Qadir; Paolo Ceppi; Sonia Brockway; Calvin Law; Liang Mu; Nikolai N Khodarev; Jung Kim; Jonathan C Zhao; William Putzbach; Andrea E Murmann; Zhuo Chen; Wenjing Chen; Xia Liu; Arthur R Salomon; Huiping Liu; Ralph R Weichselbaum; Jindan Yu; Marcus E Peter
Journal:  Cell Rep       Date:  2017-03-07       Impact factor: 9.423

3.  Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Authors:  Wei Xiao; Mohammed L Ibrahim; Priscilla S Redd; John D Klement; Chunwan Lu; Dafeng Yang; Natasha M Savage; Kebin Liu
Journal:  Mol Cancer Res       Date:  2018-11-14       Impact factor: 5.852

4.  New Advances and Challenges of Targeting Cancer Stem Cells.

Authors:  Nurmaa K Dashzeveg; Rokana Taftaf; Erika K Ramos; Luke Torre-Healy; Anastasia Chumakova; Daniel J Silver; Tyler J Alban; Maksim Sinyuk; Praveena S Thiagarajan; Awad M Jarrar; Soumya M Turaga; Caner Saygin; Erin Mulkearns-Hubert; Masahiro Hitomi; Jeremy N Rich; Stanton L Gerson; Justin D Lathia; Huiping Liu
Journal:  Cancer Res       Date:  2017-09-19       Impact factor: 12.701

5.  Identification of DISE-inducing shRNAs by monitoring cellular responses.

Authors:  Monal Patel; Marcus E Peter
Journal:  Cell Cycle       Date:  2018-04-03       Impact factor: 4.534

6.  CD95 Signaling Inhibits B Cell Receptor-Mediated Gammaherpesvirus Replication in Apoptosis-Resistant B Lymphoma Cells.

Authors:  Lingbing Tan; Chaocan Zhang; Julien Dematos; Linlin Kuang; Jae U Jung; Xiaozhen Liang
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

Review 7.  A fate worse than death: apoptosis as an oncogenic process.

Authors:  Gabriel Ichim; Stephen W G Tait
Journal:  Nat Rev Cancer       Date:  2016-07-01       Impact factor: 60.716

8.  Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism.

Authors:  William Putzbach; Quan Q Gao; Monal Patel; Stijn van Dongen; Ashley Haluck-Kangas; Aishe A Sarshad; Elizabeth T Bartom; Kwang-Youn A Kim; Denise M Scholtens; Markus Hafner; Jonathan C Zhao; Andrea E Murmann; Marcus E Peter
Journal:  Elife       Date:  2017-10-24       Impact factor: 8.140

Review 9.  DISE: A Seed-Dependent RNAi Off-Target Effect That Kills Cancer Cells.

Authors:  William Putzbach; Quan Q Gao; Monal Patel; Ashley Haluck-Kangas; Andrea E Murmann; Marcus E Peter
Journal:  Trends Cancer       Date:  2018-01-08

Review 10.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.

Authors:  Zbyslaw Sondka; Sally Bamford; Charlotte G Cole; Sari A Ward; Ian Dunham; Simon A Forbes
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.